Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus

This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.

Inclusion Criteria:

• Diabetes mellitus (type 1 or type 2)
• Patient not presently using Mixtard® 30 NovoLet®